TIDMOBD
RNS Number : 1575L
Oxford BioDynamics PLC
01 September 2023
Oxford BioDynamics PLC
Amendment: Director/PDMR Dealings
1 September 2023 - Oxford, UK - Oxford BioDynamics PLC (AIM:
OBD, "OBD" or the "Company"), a biotechnology company developing
precision medicine tests based on the EpiSwitch(R) 3D genomics
platform, announces that it has received notice from Vulpes
Investment Management Pte Ltd ("Vulpes") that on 26 January 2023
the Vulpes Testudo Fund purchased 443,673 Ordinary Shares of 1
pence each ("Ordinary Shares") at an average price of 14.75p rather
than 343,673 Ordinary Shares of 1 pence each ("Ordinary Shares") at
an average price of 14.7p as previously announced.
Therefore, Vulpes is currently interested in 28,448,756 shares
in total. Vulpes is controlled by Non-Executive Director, Stephen
Diggle, who is therefore deemed to be interested in a total of
28,448,756 shares, representing approximately 14.06% of the
Company's current issued share capital.
The corrected notification below, made in accordance with the
requirements of UK Market Abuse Regulation, provides further
details:
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Stephen Diggle
-------------------------- -------------------------------------
Reason for the notification
2
-----------------------------------------------------------------
a) Position/status Director/PDMR
-------------------------- -------------------------------------
b) Initial notification Amendment
/Amendment
-------------------------- -------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-----------------------------------------------------------------
a) Name Oxford BioDynamics Plc
-------------------------- -------------------------------------
b) LEI 2138005Y1TK258O5U928
-------------------------- -------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------
a) Description of the Ordinary Shares of 1p par value each
financial instrument,
type of instrument ISIN: GB00BD5H8572
Identification code
-------------------------- -------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
-------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
GBP0.148 100,000
----------
GBP0.148 143,673
----------
GBP0.147 200,000
----------
-------------------------- -------------------------------------
d) Aggregated information
- Aggregated volume 443,673
- Price GBP0.1475
-------------------------- -------------------------------------
e) Date of the transaction 26 January 2023
-------------------------- -------------------------------------
f) Place of the transaction XLON
-------------------------- -------------------------------------
For more information:
Oxford BioDynamics Plc Tel: +44 (0)1865 518910
Jon Burrows, CEO
Paul Stockdale, CFO
Shore Capital - Nominated Adviser Tel: +44 (0)20 7408 4090
Stephane Auton / Iain Sexton
Instinctif Partners - Financial PR Tel: +44 (0)20 7457 2020
Melanie Toyne-Sewell / Rozi Morris / Adam OxfordBioDynamics@instinctif.com
Loudon
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology
company, advancing personalized healthcare by developing and
commercializing precision medicine tests for life-changing
diseases.
Its flagship product is EpiSwitch(R) CiRT (Checkpoint Inhibitor
Response Test) for cancer, a predictive immune response profile for
immuno-oncology (IO) checkpoint inhibitor treatments, launched in
February 2022.
OBD's next commercial product will be the Prostate Screening
EpiSwitch(R) (PSE) blood test, due to be launched in Q4 2023.
In March 2021, the Company launched its first commercial
prognostic test, EpiSwitch(R) CST (Covid Severity Test) and the
first commercially available microarray kit for high-resolution 3D
genome profiling and biomarker discovery, EpiSwitch(R) Explorer
Array Kit , which is available for purchase by the life science
research community.
The Company has developed a proprietary 3D genomic biomarker
platform, EpiSwitch(R), which can build molecular diagnostic
classifiers for the prediction of response to therapy, patient
prognosis, disease diagnosis and subtyping, and residual disease
monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships
with big pharma and leading institutions including Pfizer, EMD
Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts
General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio,
including biomarker arrays, molecular diagnostic tests,
bioinformatic tools for 3D genomics and an expertly curated 3D
genome knowledgebase comprising hundreds of millions of data points
from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the
London Stock Exchange. It also has a commercial office in
Gaithersburg and a clinical laboratory in Frederick, MD, USA, and a
reference laboratory in Penang, Malaysia.
For more information, please visit the Company's website,
www.oxfordbiodynamics.com , or follow OBD on Twitter
(@OxBioDynamics) and LinkedIn .
About EpiSwitch(R)
The 3D configuration of the genome plays a crucial role in gene
regulation. By mapping this architecture and identifying abnormal
configurations, EpiSwitch(R) can be used to diagnose patients or
determine how individuals might respond to a disease or
treatment.
Built on over 10 years of research, EpiSwitch(R) is Oxford
Biodynamics' award-winning, proprietary platform that enables
screening, evaluation, validation and monitoring of 3D genomic
biomarkers. The technology is fully developed, based on testing of
over 10,000 samples in 30 disease areas, and reduced to
practice.
In addition to stratifying patients with respect to anticipated
clinical outcomes, EpiSwitch(R) data offer insights into systems
biology and the physiological manifestation of disease that are
beyond the scope of other molecular modalities. The technology has
performed well in academic medical research settings and has been
validated through its integration in biomarker discovery and
clinical development with big pharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFFLFBXKLXBBB
(END) Dow Jones Newswires
September 01, 2023 07:34 ET (11:34 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024
